Pain signal reduction

“Pain signal reduction” refers broadly to the therapeutic objective of decreasing nociceptive transmission within peripheral and central nervous system pathways responsible for perceiving and processing painful stimuli. This effect can be achieved by targeting numerous molecules—including ion channels (e.g., sodium channels like Nav1.7), receptors (e.g., opioid receptors, TRPV1), neurotransmitter systems (e.g., glutamate receptors)—that mediate neuronal excitability and synaptic transmission in nociceptive circuits. As such, “pain signal reduction” describes an outcome produced by pharmacologic modulation at multiple potential sites within complex biological networks governing sensation and response to noxious stimuli—not a discrete druggable entity itself[1][2].

Null for this entry specifically; mechanisms depend on which actual target(s) are modulated: - Opioid receptor agonism - Sodium channel blockade - Calcium channel blockade - NMDA/glutamate receptor antagonism, etc.[1]